Use of plasmids for expression of proteins from the genus Leishmania in Escherichia coli: current state and perspectives

Leishmaniosis is caused by the protozoa of the genus Leishmania with a wide spectrum of clinical and epidemiological manifestations which are characterized into four clinical groups: cutaneous, mucocutaneous, diffuse cutaneous, and visceral. American visceral leishmaniosis (AVL) or visceral leishman...

Full description

Saved in:
Bibliographic Details
Published in:Applied microbiology and biotechnology 2020-05, Vol.104 (10), p.4273-4280
Main Authors: Ribeiro, Vitor Troccoli, de Sá Leitão, Ana Laura Oliveira, de Paiva Vasconcelos, Luan Tales Costa, Filho, Marcos Antônio Oliveira, Martins, Daniella Regina Arantes, de Sousa Júnior, Francisco Canindé, dos Santos, Everaldo Silvino
Format: Article
Language:English
Subjects:
Antigens
Biomedical and Life Sciences
Biotechnology
E coli
Epidemiology
Escherichia coli
Escherichia coli - genetics
Escherichia coli - metabolism
Gene Expression
Genetic vectors
Health risks
Histidine
Leishmania
Leishmania infantum - genetics
Leishmaniasis
Leishmaniasis, Visceral - parasitology
Life Sciences
Microbial Genetics and Genomics
Microbiology
Mini-Review
Plasmids
Plasmids - genetics
Protein purification
Proteins
Protozoa
Protozoan Proteins - biosynthesis
Purification
Recombinant proteins
Recombinant Proteins - biosynthesis
Tags
Vaccines
Vectors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Leishmaniosis is caused by the protozoa of the genus Leishmania with a wide spectrum of clinical and epidemiological manifestations which are characterized into four clinical groups: cutaneous, mucocutaneous, diffuse cutaneous, and visceral. American visceral leishmaniosis (AVL) or visceral leishmaniosis (VL) has been known as the most severe form of the disease. However, despite the growing number of people exposed to the infection risk and the great effort done by the scientific community worldwide to significantly increase the knowledge about these diseases, there is no vaccine capable of preventing VL in humans. In this short review, we present some of the plasmids used for the expression of recombinant protein by Escherichia coli strains used mainly for the second generation of vaccines for leishmaniosis. It can be emphasized that currently, these vectors and hosts play an important role in developing vaccine strategies against the disease. Indeed, use of the E. coli BL21 (DE) strain is remarkable mainly due to its characteristics for being a stable protein producer as well as the use of histidine tags for antigen purification. Key points • Plasmid vectors and E. coli will continue being important for studies about leishmaniosis. • Protein purification exploiting histidine tags is a key technique.
ISSN:0175-7598
1432-0614
DOI:10.1007/s00253-020-10548-5